HX 016-9
Alternative Names: HX-016-9Latest Information Update: 04 Jul 2025
At a glance
- Originator HanX Biopharmaceuticals
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants; Vascular endothelial growth factors inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 19 May 2025 HanX Biopharmaceuticals announces intention to submit an Investigational New Drug application for Solid tumours by the end of 2026
- 07 May 2025 Preclinical trials in Solid tumours in China (Parenteral) prior to May 2025
- 25 Apr 2025 Pharmacodynamics data from a preclinical trial in Solid tumours presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)